SG49113A1 - Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl - Google Patents

Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl

Info

Publication number
SG49113A1
SG49113A1 SG1996006090A SG1996006090A SG49113A1 SG 49113 A1 SG49113 A1 SG 49113A1 SG 1996006090 A SG1996006090 A SG 1996006090A SG 1996006090 A SG1996006090 A SG 1996006090A SG 49113 A1 SG49113 A1 SG 49113A1
Authority
SG
Singapore
Prior art keywords
ctl
peptide
activation
methods
presenting cells
Prior art date
Application number
SG1996006090A
Other languages
English (en)
Inventor
Esteban Celis
Ralph Kubo
Horacio Serra
Van Tsai
Peggy Wentworth
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of SG49113A1 publication Critical patent/SG49113A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996006090A 1993-08-06 1994-08-01 Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl SG49113A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10340193A 1993-08-06 1993-08-06

Publications (1)

Publication Number Publication Date
SG49113A1 true SG49113A1 (en) 1998-05-18

Family

ID=22294982

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996006090A SG49113A1 (en) 1993-08-06 1994-08-01 Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl

Country Status (7)

Country Link
US (1) US5846827A (fr)
EP (1) EP0726941B1 (fr)
AU (1) AU7478394A (fr)
CA (1) CA2168950A1 (fr)
DE (1) DE69430315T2 (fr)
SG (1) SG49113A1 (fr)
WO (1) WO1995004817A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO1994019011A1 (fr) * 1993-02-26 1994-09-01 The Scripps Research Institute Peptides utilises pour induire des reponses aux lymphocytes t cytotoxiques contre le virus de l'hepatite b
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
CA2173138A1 (fr) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida
US6682731B1 (en) * 1994-03-24 2004-01-27 Ludwig Institute For Cancer Research Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
WO1997007128A1 (fr) * 1995-08-21 1997-02-27 Duke University Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
AU4078599A (en) * 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US6897288B1 (en) * 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
IL155307A0 (en) * 2000-10-10 2003-11-23 Univ Oklahoma Methods for isolating, identifying and purifying peptide ligands and peptide ligands produced thereby
EP1359937A4 (fr) * 2001-02-14 2004-07-28 Genzyme Corp Ligands peptidiques modifies
DE10109224A1 (de) * 2001-02-26 2002-09-05 Bayer Ag Flammwidrige Polycarbonat-Zusammensetzungen mit erhöhter Chemikalienbeständigkeit
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
AU2002322009A1 (en) * 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
EP1435776A4 (fr) 2001-09-24 2006-01-25 Univ Pittsburgh Vaccin anticancereux, methodes diagnostiques et reactifs
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
EP1556072B1 (fr) 2002-09-17 2010-05-19 Antigen Express, Inc. Vaccins a base d'epitope antigenique ii-key peptidique hybride
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
WO2004076652A1 (fr) * 2003-02-25 2004-09-10 Tokai University Milieu pour cellules souches destinees a etre utilisees pour regenerer un disque intervertebral et regeneration d'un disque intervertebral utilisant des cellules souches
WO2005012502A2 (fr) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Procedes d'identification de variants optimaux d'epitopes peptidiques
US20080274129A1 (en) 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
US20070298051A1 (en) * 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
EP1776583A4 (fr) * 2004-02-26 2009-04-29 Immunovative Therapies Ltd Procedes de preparation de lymphocytes t pour therapie cellulaire
DK1749090T3 (en) 2004-03-01 2017-09-04 Immunovative Therapies Ltd CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION
WO2006009838A2 (fr) 2004-06-17 2006-01-26 Beckman Coulter, Inc. Epitopes de mycobacterium tuberculosis et leurs procedes d'utilisation
WO2007044033A2 (fr) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Récepteur non restreint par le cmh cloné de l'antigène spécifique de tumeur muc1 pour applications thérapeutiques et diagnostiques
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
EP2079830B1 (fr) 2006-10-04 2016-08-17 Janssen Pharmaceutica NV Préparation de cellules présentant l'antigène artificielles inactivées et leur utilisation dans des thérapies cellulaires
EP2300023A2 (fr) * 2008-05-16 2011-03-30 Genelux Corporation Microorganismes pour la prévention et le traitement de néoplasmes accompagnant une thérapie cellulaire
WO2010011994A2 (fr) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides et leurs utilisations
WO2010088393A2 (fr) * 2009-01-28 2010-08-05 Antigen Express, Inc. Peptides hybrides li-key modulant la réponse immunitaire à la grippe
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
AU2010239478A1 (en) * 2009-04-20 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic epitopes of NGEP antigen
DK2453914T3 (en) * 2009-07-16 2018-10-08 Vaxil Biotherapeutics Ltd ANTIGEN-SPECIFIC MULTIPLE PIT-BASED ANTI-INFECTIOUS VACCINES
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CA2838046C (fr) 2011-05-03 2023-03-07 Immunovative Therapies, Ltd. Induction d'il-12 par immunotherapie
KR102202460B1 (ko) 2011-05-03 2021-01-14 이뮤노베이티브 테라피스, 엘티디. 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US20160320408A1 (en) 2013-12-19 2016-11-03 Opexa Therapeutics, Inc. Methods of t cell epitope profiling, making t cell compositions, and treating diseases
WO2016100977A1 (fr) 2014-12-19 2016-06-23 The Broad Institute Inc. Procédés pour le profilage du répertoire de récepteurs de cellules t
US20200215110A1 (en) * 2016-09-09 2020-07-09 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases
FI3580561T3 (fi) 2017-02-12 2023-12-12 Biontech Us Inc Hla-pohjaiset menetelmät ja koostumukset sekä niiden käyttö
AU2019404547A1 (en) 2018-12-21 2021-07-22 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
US20220364059A1 (en) 2019-07-05 2022-11-17 Case Western Reserve University Priming media and methods for stem cell culture and therapy
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081029A (en) * 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
DE69326064T2 (de) * 1992-05-26 2000-05-25 Rijksuniversiteit Te Leiden Le Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions

Also Published As

Publication number Publication date
EP0726941B1 (fr) 2002-04-03
AU7478394A (en) 1995-02-28
US5846827A (en) 1998-12-08
EP0726941A1 (fr) 1996-08-21
EP0726941A4 (fr) 1999-06-16
DE69430315D1 (de) 2002-05-08
CA2168950A1 (fr) 1995-02-16
DE69430315T2 (de) 2002-11-21
WO1995004817A1 (fr) 1995-02-16

Similar Documents

Publication Publication Date Title
SG49113A1 (en) Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
AU4472793A (en) Methods for diagnosis and therapy using defined regions of the T cell antigen receptor
EP1012238A4 (fr) Cellules a peptides ou a antigenes charges de peptides
EP0743820A4 (fr) Traitement d'affections propres aux mammiferes par des myoblastes
AU4670293A (en) Non-invasive testing
AU3127193A (en) Portable non-invasive testing apparatus
AU5590098A (en) Endoprosthetic device with therapeutic compound
IL134842A0 (en) Method of delivering genes to antigen presenting cells of the skin
GB2289343B (en) Therapy tomograph with homogeneity device
AU6785987A (en) Selecting and testing antibodies for cancer therapy
ZA983445B (en) Apparatus and process for the low-temperature storage of biological preparations
IL106037A0 (en) Therapeutic and diagnostic methods based on neurotrophin-4-expression
AU7992994A (en) Immunoassay for the dectection of human autoantibodies
AU8381191A (en) Anchoring device
AU6862591A (en) Anchoring device
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU5781886A (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
AU4416189A (en) Therapeutic and diagnostic methods using soluble t cell surface molecules
AU1524095A (en) Ex vivo activation of immune cells
AU5615594A (en) Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
AU4122689A (en) Human rhinovirus peptides
AUPM598394A0 (en) Transformed human hepatoma cell line which releases insulin
GB2227988B (en) An omnidirectional burial anchor
AU2808795A (en) Seismic anchor